search
Back to results

Evaluating Stress Response and Anxiety Score in Paediatric Patients

Primary Purpose

Anxiety and Fear, Anesthesia

Status
Completed
Phase
Phase 2
Locations
Malaysia
Study Type
Interventional
Intervention
Dexmedetomidine
Placebo
Sponsored by
Universiti Sains Malaysia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Anxiety and Fear focused on measuring Paediatric, Intranasal, General anaesthesia, Dexmedetomidine, Anxiety score, cortisol

Eligibility Criteria

1 Year - 12 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Pediatric patients age 1-12 years old
  • Weight of patient between 10 - 60 kgs
  • American Society of Anesthesiologist (ASA) I or II
  • Scheduled for elective and emergency surgeries
  • Caregivers able to understand and provide informed consent

Exclusion Criteria:

  • Allergy to study drugs (dexmedetomidine, morphine, paracetamol etc.)
  • Special need Children (Cerebral palsy, down syndrome, ADHD, ASD)
  • Serious cardiac/respiratory diseases.
  • Children with neuromuscular disorders or neurological diseases (epilepsy etc)
  • Children with Metabolic disorders
  • Difficult airway cases
  • Children on any kind of steroid therapy / HPA diseases

Sites / Locations

  • Hospital Universiti Sains Malaysia

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Dexmedetomidine

Placebo

Arm Description

Intranasal dexmedetomidine 1mcg/kg

Intranasal normal saline equivalent to (1mcg/kg dose of dexmedetomidine)

Outcomes

Primary Outcome Measures

Evaluating stress response
Evaluating stress response by measuring serum cortisol level (nmol/L)
Evaluating anxiety score
To compare mean anxiety score using modified Yale Preoperative Anxiety Scales (m-YPAS)

Secondary Outcome Measures

Safety profile of Intranasal Dexmedetomidine in paediatric patients
Monitoring the haemodynamic parameters (blood pressure in mmHg)
Safety profile of Intranasal Dexmedetomidine in paediatric patients
Monitoring the haemodynamic parameters (heart rate in beats per minute)
Safety profile of Intranasal Dexmedetomidine in paediatric patients
Monitoring the haemodynamic parameters (Oxygen saturation in percentage)

Full Information

First Posted
August 4, 2020
Last Updated
October 17, 2021
Sponsor
Universiti Sains Malaysia
search

1. Study Identification

Unique Protocol Identification Number
NCT04526652
Brief Title
Evaluating Stress Response and Anxiety Score in Paediatric Patients
Official Title
Evaluating Stress Response and Anxiety Score in Paediatric Patients Sedated With Intranasal Dexmedetomidine
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
December 1, 2020 (Actual)
Primary Completion Date
July 31, 2021 (Actual)
Study Completion Date
August 1, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universiti Sains Malaysia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To date, there have been no studies done relating serum cortisol levels and intranasal dexmedetomidine sedation. However, there was a behavioral study done on pediatric patients confirming reduction serum cortisol levels with perioperative dialogue intervention.There have been a number of studies done on adult patients indicating that dexmedetomidine was indeed capable of reducing level of anxiety with evidence of lower serum cortisol levels. Hence, we postulated that intranasal dexmedetomidine administration in pediatric patients will lower the serum cortisol levels but we need to evaluate the extent of reduction.
Detailed Description
Justification of study With increase in number of pediatric patients undergoing surgery, efforts need to be placed on improving quality of perioperative care and patient comfort Intranasal administration of sedative agents will be far more comfortable and create a better environment for patients as most children have a fear of needles and may resist intravenous drug administration Intranasal administration is also a far simpler and less time-consuming technique with good bioavailability of administered drugs Reduction in postoperative analgesia requirement will result in early return to daily life activities, early discharge and overall reduced length of stay and hospital costs Pre and intraoperative All perioperative data will be collected by an investigator who is blinded to the patient's allocation. Once the caregiver has agreed and consented to participate in this study, upon admission (1 day prior to scheduled surgery) a baseline serum cortisol level will be taken concurrent with IV line setting and blood investigations. The fasting time for all patients will be at least 6 hours prior to surgery with clear fluids being allowed up to 2 hours prior to surgery. On the day of surgery, the patient and caregiver will be called upon 1 hour prior to operating time and baseline hemodynamic parameters will be recorded (blood pressure, heart rate and pulse oximetry SpO2). Baseline Modified Yale Preoperative Anxiety Scale (m-YPAS) will be used as an assessment tool for measuring level of preoperative anxiety. Baseline Modified Yale Preoperative Anxiety scale (m-YPAS) is an established and recognized tool for assessment of pediatric anxiety levels preoperatively. It is an observational checklist each consisting of four to six distinct behavioral descriptions. Four categories of behavior are assessed: activity, vocalizations, emotional expressivity, and state of apparent arousal. Partial weights are used to calculate a total score ranging from 23 (low anxiety) to 100 (high anxiety). Previous research has shown good to excellent inter and intra-observer reliability and validity. Once the baseline parameters have been recorded, patient will receive the medication previously assigned via randomization delivered via mucosal atomizer device (MAD). Drugs will be administered by anesthetist or anesthetic medical officer only in safe setting with drugs for resuscitation and monitoring equipment available. They will be briefed on the workflow and timing of drug administration accordingly. The person responsible for delivering the medication will be blinded. Hemodynamic parameters will be charted at 10 minutes intervals after the study medications have been served. Rescue drugs IV atropine 10 - 20mcg/kg will be given if the patient develops bradycardia (less than 2SDs for age) and fluid boluses if blood pressure drops to more than 20% of baseline or below 2SD of blood pressure for age. 2nd Modified Yale Preoperative Anxiety Scale (m-YPAS) will be assessed 10 minutes after delivering the study medications. This is followed by sedation score after 30 minutes and 3rd. m-YPAS if indicated. Sedation and behavior score is a simplified scoring system that is based on observational charting. It comprises of 2 domains ranging from alert, awake, crying and resisting to asleep and not responding to mild prodding or shaking while being calm and cooperative. Higher scores indicate a higher level of sedation and are more favorable. Once the patient has arrived in the operation theatre, the SpO2 monitoring probe will be attached and intravenous induction is carried out with IV Propofol 4 - 5mg/kg. This is followed by applying other standard monitoring appliances such as blood pressure cuff and ECG electrodes. IV fentanyl 1-2mcg/kg to obtund the laryngeal reflex and paralysis with IV esmeron 0.6-1mg/kg. Appropriate size endotracheal tubes (ETT) or laryngeal mask airway (LMA) will be inserted accordingly to secure the airway. 2nd sample of serum cortisol level will be taken within 10 minutes of induction of anesthesia. Maintenance of anesthesia with sevoflurane aiming at 1.0 minimum alveolar concentration (MAC). Intravenous fluid will be replaced according to (Holiday Segar Formula) using either HM solution or sterofundin. IV paracetamol 15mg/kg will be given pre-emptively, followed by IV morphine 0.1mg/kg. IV Fentanyl boluses 0.5-1mcg/kg will be served if required based on the hemodynamic parameters. Postoperative Postoperatively patient will be monitored in recovery room for 30 minutes and pain will be assessed using Wong Baker Faces pain rating scale/FLACC for smaller children. Rescue analgesic IV Fentanyl 0.5-1mcg/kg will be given if required. The total requirement of IV Fentanyl and the discharge time will be recorded for reference. Wong Baker Faces scale is tool created with children to help them communicate their pain. Now the scale is used around the world with people ages 3 and older, facilitating communication and improving assessment so pain management can be addressed accordingly. There are 6 faces with each face representing a person who has no pain (hurt), or some, or a lot of pain. The patient chooses the face that best depicts the pain they are experiencing. The FLACC scale or Face, Legs, Activity, Cry, Consolability scale is a measurement used to assess pain for children between the ages of 2 months and 7 years or individuals that are unable to communicate their pain. It is an observational based scale. The scale is scored in a range of 0-10 with 0 representing no pain. The scale has five criteria, which are each assigned a score of 0, 1 or 2. Higher scores indicate higher pain. Statistical Analysis The analyses will be performed using the IBM SPSS Statistics for Windows Version 21.0. The data will be manually entered into the software before the cleaning process takes place. The cleaning process is crucial to prevent any errors that may skew the results. After that, the actual analysis process will be carried out. In this study, descriptive statistics will be employed for selected variables. The findings will be presented based on the types of data and their distribution. Categorical Data, will be presented as frequencies and percentage. Numerical Data will be presented as means and standard deviations if normally distributed, and if not, as medians and interquartile ranges. Comparison of Numerical Data between two independent groups that are normally distributed will be analyzed using the Independent t-test, while Mann-Whitney test will be used if the data for two independent groups are not normally distributed. Hemodynamic parameters measurement (objective 3) will be analyzed using repeated measures ANOVA while Friedman test will be used if the Numerical Data are not normally distributed. All probability values are two-sided, and a level of significance of less than 0.05 (p-value < 0.05) will be considered as statistically significant

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anxiety and Fear, Anesthesia
Keywords
Paediatric, Intranasal, General anaesthesia, Dexmedetomidine, Anxiety score, cortisol

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
Randomization of paediatric patients for general anaesthesia one arm: Intranasal dexmedetomidine another arm: Intranasal normal saline (placebo)
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Double blinded study
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Dexmedetomidine
Arm Type
Active Comparator
Arm Description
Intranasal dexmedetomidine 1mcg/kg
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Intranasal normal saline equivalent to (1mcg/kg dose of dexmedetomidine)
Intervention Type
Drug
Intervention Name(s)
Dexmedetomidine
Intervention Description
Evaluating anxiety score in both arms
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Evaluating anxiety score in both arms
Primary Outcome Measure Information:
Title
Evaluating stress response
Description
Evaluating stress response by measuring serum cortisol level (nmol/L)
Time Frame
Baseline: (before giving study drugs) and 1 to half an hour after drugs given
Title
Evaluating anxiety score
Description
To compare mean anxiety score using modified Yale Preoperative Anxiety Scales (m-YPAS)
Time Frame
Baseline:(before giving study drugs) and 1 to half an hour after drugs given
Secondary Outcome Measure Information:
Title
Safety profile of Intranasal Dexmedetomidine in paediatric patients
Description
Monitoring the haemodynamic parameters (blood pressure in mmHg)
Time Frame
Baseline and 10 minutes interval after study drugs given
Title
Safety profile of Intranasal Dexmedetomidine in paediatric patients
Description
Monitoring the haemodynamic parameters (heart rate in beats per minute)
Time Frame
Baseline and 10 minutes interval after study drugs given
Title
Safety profile of Intranasal Dexmedetomidine in paediatric patients
Description
Monitoring the haemodynamic parameters (Oxygen saturation in percentage)
Time Frame
Baseline and 10 minutes interval after study drugs given

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Pediatric patients age 1-12 years old Weight of patient between 10 - 60 kgs American Society of Anesthesiologist (ASA) I or II Scheduled for elective and emergency surgeries Caregivers able to understand and provide informed consent Exclusion Criteria: Allergy to study drugs (dexmedetomidine, morphine, paracetamol etc.) Special need Children (Cerebral palsy, down syndrome, ADHD, ASD) Serious cardiac/respiratory diseases. Children with neuromuscular disorders or neurological diseases (epilepsy etc) Children with Metabolic disorders Difficult airway cases Children on any kind of steroid therapy / HPA diseases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Huda Zainal Abidin, MD
Organizational Affiliation
Universiti Sains Malaysia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universiti Sains Malaysia
City
Kota Bharu
State/Province
Kelantan
ZIP/Postal Code
15200
Country
Malaysia

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
IPD will be considered for sharing if the the data is to be used for related study
Citations:
PubMed Identifier
16879517
Citation
Isik B, Arslan M, Tunga AD, Kurtipek O. Dexmedetomidine decreases emergence agitation in pediatric patients after sevoflurane anesthesia without surgery. Paediatr Anaesth. 2006 Jul;16(7):748-53. doi: 10.1111/j.1460-9592.2006.01845.x. Erratum In: Paediatr Anaesth. 2006 Jul;16(7):811.
Results Reference
background
PubMed Identifier
10702460
Citation
Hall JE, Uhrich TD, Barney JA, Arain SR, Ebert TJ. Sedative, amnestic, and analgesic properties of small-dose dexmedetomidine infusions. Anesth Analg. 2000 Mar;90(3):699-705. doi: 10.1097/00000539-200003000-00035.
Results Reference
background
PubMed Identifier
22950484
Citation
Yuen VM, Hui TW, Irwin MG, Yao TJ, Chan L, Wong GL, Shahnaz Hasan M, Shariffuddin II. A randomised comparison of two intranasal dexmedetomidine doses for premedication in children. Anaesthesia. 2012 Nov;67(11):1210-6. doi: 10.1111/j.1365-2044.2012.07309.x. Epub 2012 Sep 5.
Results Reference
background
PubMed Identifier
20645951
Citation
Yuen VM, Hui TW, Irwin MG, Yao TJ, Wong GL, Yuen MK. Optimal timing for the administration of intranasal dexmedetomidine for premedication in children. Anaesthesia. 2010 Sep;65(9):922-9. doi: 10.1111/j.1365-2044.2010.06453.x.
Results Reference
background
PubMed Identifier
22268591
Citation
Akin A, Bayram A, Esmaoglu A, Tosun Z, Aksu R, Altuntas R, Boyaci A. Dexmedetomidine vs midazolam for premedication of pediatric patients undergoing anesthesia. Paediatr Anaesth. 2012 Sep;22(9):871-6. doi: 10.1111/j.1460-9592.2012.03802.x. Epub 2012 Jan 23.
Results Reference
background

Learn more about this trial

Evaluating Stress Response and Anxiety Score in Paediatric Patients

We'll reach out to this number within 24 hrs